Celldex Therapeutics CLDX Stock
Celldex Therapeutics Price Chart
Celldex Therapeutics CLDX Financial and Trading Overview
| Celldex Therapeutics stock price | 36.9 USD |
| Previous Close | 38.1 USD |
| Open | 38.45 USD |
| Bid | 32.33 USD x 100 |
| Ask | 43.69 USD x 100 |
| Day's Range | 36.84 - 38.59 USD |
| 52 Week Range | 22.1 - 45.14 USD |
| Volume | 1.03M USD |
| Avg. Volume | 1.01M USD |
| Market Cap | 2.9B USD |
| Beta (5Y Monthly) | 0.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.35 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 58.79 USD |
CLDX Valuation Measures
| Enterprise Value | 2.28B USD |
| Trailing P/E | N/A |
| Forward P/E | -8.730339 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 18340.127 |
| Price/Book (mrq) | 4.053609 |
| Enterprise Value/Revenue | 14425.9 |
| Enterprise Value/EBITDA | -7.069 |
Trading Information
Celldex Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.84 |
| 52-Week Change | 55.82% |
| S&P500 52-Week Change | 15.30% |
| 52 Week High | 45.14 USD |
| 52 Week Low | 22.1 USD |
| 50-Day Moving Average | 39.13 USD |
| 200-Day Moving Average | 31.76 USD |
CLDX Share Statistics
| Avg. Volume (3 month) | 1.01M USD |
| Avg. Daily Volume (10-Days) | 579.49K USD |
| Shares Outstanding | 78.53M |
| Float | 73.02M |
| Short Ratio | 10.28 |
| % Held by Insiders | 0.27% |
| % Held by Institutions | 110.22% |
| Shares Short | 8.64M |
| Short % of Float | 13.05% |
| Short % of Shares Outstanding | 11.00% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -366468.19% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -27.61% |
| Return on Equity (ttm) | -43.87% |
Income Statement
| Revenue (ttm) | 158K USD |
| Revenue Per Share (ttm) | 0.002 USD |
| Quarterly Revenue Growth (yoy) | -97.00000000000000000000000000000000% |
| Gross Profit (ttm) | -278648992 USD |
| EBITDA | -322432000 USD |
| Net Income Avi to Common (ttm) | -300548992 USD |
| Diluted EPS (ttm) | -4.35 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 717.59M USD |
| Total Cash Per Share (mrq) | 9.14 USD |
| Total Debt (mrq) | 4.9M USD |
| Total Debt/Equity (mrq) | 0.69 USD |
| Current Ratio (mrq) | 11.821 |
| Book Value Per Share (mrq) | 9.103 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -235566000 USD |
| Levered Free Cash Flow (ttm) | -133080496 USD |
Profile of Celldex Therapeutics
| Country | United States |
| State | NJ |
| City | Hampton |
| Address | Perryville III Building |
| ZIP | 08827 |
| Phone | 908 200 7500 |
| Website | https://www.celldex.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 198 |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Q&A For Celldex Therapeutics Stock
What is a current CLDX stock price?
Celldex Therapeutics CLDX stock price today per share is 36.9 USD.
How to purchase Celldex Therapeutics stock?
You can buy CLDX shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Celldex Therapeutics?
The stock symbol or ticker of Celldex Therapeutics is CLDX.
Which industry does the Celldex Therapeutics company belong to?
The Celldex Therapeutics industry is Biotechnology.
How many shares does Celldex Therapeutics have in circulation?
The max supply of Celldex Therapeutics shares is 78.53M.
What is Celldex Therapeutics Price to Earnings Ratio (PE Ratio)?
Celldex Therapeutics PE Ratio is now.
What was Celldex Therapeutics earnings per share over the trailing 12 months (TTM)?
Celldex Therapeutics EPS is -4.35 USD over the trailing 12 months.
Which sector does the Celldex Therapeutics company belong to?
The Celldex Therapeutics sector is Healthcare.
Celldex Therapeutics CLDX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26333.04 USD — |
+0.96
|
5.66B USD — | 26283.11 USD — | 26431.22 USD — | — - | 5.66B USD — |
|
US Tech Health Care
IXHC
US
|
1293.65 USD — |
+0.08
|
— — | 1293.64 USD — | 1310.12 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
32519.98 USD — |
+0.97
|
— — | 32458.33 USD — | 32641.23 USD — | — - | — — |
|
US Tech US 700 Small Cap Index
NQUS700SC
US
|
3079.71 USD — |
+0.6
|
— — | 3078.59 USD — | 3102.26 USD — | — - | — — |
|
US Tech Biotechnology Total Retu
XNBI
US
|
7562.93 USD — |
+0.05
|
— — | 7562.7 USD — | 7651.81 USD — | — - | — — |
|
US Tech Capital Market Composite
RCMP
US
|
137.24 USD — |
+0.22
|
— — | 137.22 USD — | 139.48 USD — | — - | — — |
|
US Tech AlphaDEX Multi Cap Growt
NQDXUSMLTCG
US
|
3899.6 USD — |
+1.07
|
— — | 3895.08 USD — | 3912.26 USD — | — - | — — |
- {{ link.label }} {{link}}
